Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

Evaluation of Eravacycline: a Novel Flourocycline.

Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SC, Rybak MJ.

Pharmacotherapy. 2020 Jan 15. doi: 10.1002/phar.2366. [Epub ahead of print] Review.

PMID:
31944332
2.

Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments.

McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, Ouellette K, Vasina L, Haddad F, Rybak MJ, Zervos MJ, Sakoulas G, Rose WE.

Open Forum Infect Dis. 2019 Dec 31;7(1):ofz538. doi: 10.1093/ofid/ofz538. eCollection 2020 Jan.

3.

Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections.

Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, Melvin SM, Steed ME, Finch NA, Morrisette T, Estrada SJ, Rosenberg JR, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02291-19. doi: 10.1128/AAC.02291-19. [Epub ahead of print]

PMID:
31932379
4.

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, Claeys KC, Rosenberg JR, Davis SL, Rybak MJ.

Open Forum Infect Dis. 2019 Dec 6;6(12):ofz522. doi: 10.1093/ofid/ofz522. eCollection 2019 Dec.

5.

Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations.

Morrisette T, Kebriaei R, Lev KL, Morales S, Rybak MJ.

Pharmacotherapy. 2019 Dec 24. doi: 10.1002/phar.2358. [Epub ahead of print] Review.

PMID:
31872889
6.

Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated.

Ortwine JK, Zasowski EJ, Pogue JM, Hanni C, Giuliano C, Casapao AM, Mynatt R, Rybak MJ.

Infect Dis Ther. 2019 Dec;8(4):627-640. doi: 10.1007/s40121-019-00268-3. Epub 2019 Oct 21.

7.

Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.

Trinh TD, Smith JR, Rybak MJ.

Pharmacotherapy. 2019 Nov;39(11):1077-1094. doi: 10.1002/phar.2326. Epub 2019 Oct 14. Review.

PMID:
31487056
8.

Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

Trinh TD, Jorgensen SCJ, Zasowski EJ, Claeys KC, Lagnf AM, Estrada SJ, Delaportes DJ, Huang V, Klinker KP, Kaye KS, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e01007-19. doi: 10.1128/AAC.01007-19. Print 2019 Nov.

PMID:
31405859
9.

Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study.

Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, Abdul-Mutakabbir JC, Alosaimy S, Mynatt RP, Davis SL, Rybak MJ.

Clin Infect Dis. 2019 Aug 12. pii: ciz746. doi: 10.1093/cid/ciz746. [Epub ahead of print]

PMID:
31404468
10.

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin.

Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, Rybak MJ.

Open Forum Infect Dis. 2019 Feb 27;6(7):ofz077. doi: 10.1093/ofid/ofz077. eCollection 2019 Jul.

11.

Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Int J Antimicrob Agents. 2019 Sep;54(3):346-350. doi: 10.1016/j.ijantimicag.2019.07.002. Epub 2019 Jul 5.

PMID:
31284042
12.

Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.

Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00779-19. doi: 10.1128/AAC.00779-19. Print 2019 Aug.

PMID:
31182535
13.

Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network.

Rhodes NJ, Wagner JL, Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00327-19. doi: 10.1128/AAC.00327-19. Print 2019 Jul.

14.

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Lv X, Alder J, Li L, O'Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox MH.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02252-18. doi: 10.1128/AAC.02252-18. Print 2019 Jul.

15.

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin.

Zasowski EJ, Trinh TD, Atwan SM, Merzlyakova M, Langf AM, Bhatia S, Rybak MJ.

Open Forum Infect Dis. 2019 Apr 3;6(4):ofz079. doi: 10.1093/ofid/ofz079. eCollection 2019 Apr. Retraction in: Open Forum Infect Dis. 2019 Feb 27;6(7):ofz077.

16.

Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Kebriaei R, Rice SA, Stamper KC, Seepersaud R, Garcia-de-la-Maria C, Mishra NN, Miro JM, Arias CA, Tran TT, Sullam PM, Bayer AS, Rybak MJ.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00386-19. doi: 10.1128/AAC.00386-19. Print 2019 Jun.

17.

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.

Corey GR, McKinnell JA, Rybak MJ.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S191-S192. doi: 10.1093/cid/ciy1089. No abstract available.

18.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

19.

Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin.

Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):155-170. doi: 10.1007/s40121-019-0239-0. Epub 2019 Mar 9. Review.

20.

Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.

Rolston KVI, Jamal M, Nesher L, Raad I, Rice SA, Rybak MJ, Prince RA.

J Glob Antimicrob Resist. 2019 Jun;17:16-18. doi: 10.1016/j.jgar.2019.02.018. Epub 2019 Mar 5. No abstract available.

PMID:
30844496
21.

Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections.

Jorgensen SCJ, Lagnf AM, Bhatia S, Singh NB, Shammout LK, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):229-242. doi: 10.1007/s40121-019-0238-1. Epub 2019 Feb 19.

22.

A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.

Jorgensen SCJ, Lagnf AM, Bhatia S, Rybak MJ.

Eur J Clin Microbiol Infect Dis. 2019 May;38(5):843-850. doi: 10.1007/s10096-018-03464-0. Epub 2019 Feb 8.

PMID:
30734879
23.

Reply to Koehler et al.

Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL.

Clin Infect Dis. 2019 Aug 16;69(5):901-902. doi: 10.1093/cid/ciz057. No abstract available.

PMID:
30715221
24.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Aug 16;69(5):903-904. doi: 10.1093/cid/ciz081. No abstract available.

PMID:
30715199
25.

Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.

Kebriaei R, Rice SA, Stamper KC, Rybak MJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01743-18. doi: 10.1128/AAC.01743-18. Print 2019 Apr.

26.

The Optimal Use of the Polymyxins Before Their Time Is Up.

Alosaimy S, Jorgensen SCJ, Rybak MJ.

Pharmacotherapy. 2019 Jan;39(1):7-9. doi: 10.1002/phar.2207. Epub 2019 Jan 8. No abstract available.

PMID:
30623457
27.

Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study.

Rybak MJ, Zasowski EJ, Jorgensen SCJ, Lagnf AM, Davis SL, Mendelsohn AB, Margaritis V.

Infect Dis Ther. 2019 Mar;8(1):75-85. doi: 10.1007/s40121-018-0227-9. Epub 2018 Dec 18.

28.

Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis.

Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA, Sullam PM, Bayer AS, Arias CA.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18. doi: 10.1128/AAC.01531-18. Print 2019 Feb.

29.

Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer.

Jorgensen SCJ, Lagnf AM, Bhatia S, Shamim MD, Rybak MJ.

J Antimicrob Chemother. 2019 Feb 1;74(2):489-498. doi: 10.1093/jac/dky452.

PMID:
30418557
30.

Making the change to area under the curve-based vancomycin dosing.

Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, Pogue JM.

Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17. No abstract available.

PMID:
30333114
31.

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms.

Jorgensen SCJ, Rybak MJ.

Infect Dis Ther. 2018 Dec;7(4):401-405. doi: 10.1007/s40121-018-0215-0. Epub 2018 Oct 3. No abstract available.

32.

Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.

Xhemali X, Smith JR, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ.

J Antimicrob Chemother. 2019 Jan 1;74(1):82-86. doi: 10.1093/jac/dky376.

PMID:
30260409
33.

Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting.

Claeys KC, Zasowski EJ, Lagnf AM, Sabagha N, Levine DP, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Dec;7(4):495-507. doi: 10.1007/s40121-018-0212-3. Epub 2018 Sep 22.

34.

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient.

Jorgensen SCJ, McDonald P, Mynatt RP, Pogue JM, Lerner SA, Dhar S, Salimnia H, Rybak MJ.

J Antimicrob Chemother. 2018 Dec 1;73(12):3529-3531. doi: 10.1093/jac/dky346. No abstract available.

PMID:
30188993
35.

Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 May 2;68(10):1650-1657. doi: 10.1093/cid/ciy749.

36.

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA.

Bhise K, Sau S, Kebriaei R, Rice SA, Stamper KC, Alsaab HO, Rybak MJ, Iyer AK.

Materials (Basel). 2018 Jul 20;11(7). pii: E1245. doi: 10.3390/ma11071245.

37.

Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.

Singh NB, Yim J, Jahanbakhsh S, Sakoulas G, Rybak MJ.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):363-370. doi: 10.1016/j.diagmicrobio.2018.03.020. Epub 2018 Apr 7.

PMID:
29807674
38.

Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Jahanbakhsh S, Singh NB, Yim J, Rose WE, Rybak MJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00567-18. doi: 10.1128/AAC.00567-18. Print 2018 Aug.

39.

Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.

Kebriaei R, Rice SA, Singh KV, Stamper KC, Dinh AQ, Rios R, Diaz L, Murray BE, Munita JM, Tran TT, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00315-18. doi: 10.1128/AAC.00315-18. Print 2018 Aug.

40.

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Jun;7(2):197-217. doi: 10.1007/s40121-018-0198-x. Epub 2018 Mar 31. Review.

41.
42.

Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Smith JR, Yim J, Rice S, Stamper K, Kebriaei R, Rybak MJ.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00101-18. doi: 10.1128/AAC.00101-18. Print 2018 May.

43.

Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections.

Trinh TD, Zasowski EJ, Claeys KC, Casapao AM, Compton M, Lagnf A, Kidambi SD, Levine DP, Rybak MJ.

Infect Dis Ther. 2018 Mar;7(1):161-169. doi: 10.1007/s40121-018-0187-0. Epub 2018 Feb 22.

44.

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.

Jorgensen SCJ, Rybak MJ.

Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28. Review.

PMID:
29427523
45.

A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL.

Clin Infect Dis. 2018 Jul 2;67(2):303-309. doi: 10.1093/cid/ciy064. Review.

46.

Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis.

Claeys KC, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Mar;7(1):135-146. doi: 10.1007/s40121-017-0179-5. Epub 2017 Nov 21.

47.

Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, Rybak MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01684-17. doi: 10.1128/AAC.01684-17. Print 2018 Jan.

48.

Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil.

Aires CAM, Rybak MJ, Yim J, Pereira PS, Rocha-de-Souza CM, Albano RM, Cavalcanti VO, D'Alincourt Carvalho-Assef AP, Gomes MZR, Asensi MD.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):324-327. doi: 10.1016/j.diagmicrobio.2017.08.017. Epub 2017 Aug 25.

49.

A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01293-17. doi: 10.1128/AAC.01293-17. Print 2017 Dec.

50.

Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.

Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ.

Diagn Microbiol Infect Dis. 2017 Sep;89(1):61-66. doi: 10.1016/j.diagmicrobio.2017.06.009. Epub 2017 Jun 19.

PMID:
28716451

Supplemental Content

Loading ...
Support Center